Despite its success, resistance to ICB is routinely observed among cancer patients, where lower levels of mutation burden, and reduced intra-tumoural PD-1/PD-L1 and MHC-I expression are common drivers of ICB resistance [305]. The gene discussed is PDCD1; the disease is cancer.